DD HST-NEETs

Phase 1Biologic

CCatherine Bollard

DD HST-NEETs is one of 2 biologic programs targeting HIV-Infected Individuals. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV-Infected IndividualsActive, not recruiting

HIV-Infected IndividualsPhase 1

Active, not recruiting

Competition

Competitive Landscape

1 competitor in HIV-Infected Individuals

#DrugCompanyPhaseTrials

LP-98

SShanxi Kangbao Biological Product Co., Ltd.

Phase 2

1 2

DD HST-NEETs

CCatherine Bollard

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

HIV-Infected Individuals

NCT04248192

Clinical

Trials by Indication[1]

HIV-Infected Individuals1 trial

A Study to Evaluate the Safety, Immunologic, and Virologic RESponses of Donor Derived (DD) HIV-Specific T-cells (HST) With Non-escaped Epitope Targeting (NEETs) in HIV-Infected Individuals on Antiretroviral Therapy Following Allogeneic Bone Marrow Transplantation (alloRESIST)

Active, not recruiting·CCatherine Bollard·Phase 1·NCT04248192·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DD HST-NEETs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DD HST-NEETs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DD HST-NEETs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Catherine Bollard company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCatherine Bollard

DD HST-NEETs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

HIV-Infected Individuals1 trial

References

Drug Info

Quick Facts

Related News